
Opinion|Videos|April 4, 2025
Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might bispecifics be incorporated earlier in the lines of treatment for certain cancers?
- What steps can be taken to improve access to bispecific therapies in underserved or rural community settings?
- How can partnerships between academic centers, manufacturers, and community practices help accelerate the adoption of bispecific antibodies?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
The Next Frontier in Hepatitis B Functional and Virologic Cure
5






